Ocrevus

diverse clinical trial diversity

Biotech

Genentech aims to change 'one size' approach to MS trials

A half decade after Genentech’s MS drug Ocrevus secured FDA approval, the Roche unit isn’t resting on its laurels.

Gabrielle Masson Sep 27, 2022 10:00am

Roche

Roche delays DMD drug, amends MS trials in face of Ukraine war

Apr 25, 2022 11:41am